Journal of Vascular Surgery
Volume 46, Issue 6 , Pages 1160-1166 , December 2007

The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure

Presented at the Thirty-first Annual Meeting of the Southern Association for Vascular Surgery, Rio Grande, Puerto Rico, Jan 17-20, 2007.

  • Robert Scott Brumberg, DO

      Affiliations

    • Division of Vascular and Endovascular Surgery, University of South Florida Health, Tampa, Fla
    • ,
  • Martin R. Back, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, University of South Florida Health, Tampa, Fla
    • Corresponding Author InformationReprint requests: Martin R. Back, MD, USF Vascular, HMT 650, 4 Columbia Dr, Tampa, FL 33606.
    • ,
  • Paul A. Armstrong, DO

      Affiliations

    • Division of Vascular and Endovascular Surgery, University of South Florida Health, Tampa, Fla
    • ,
  • David Cuthbertson, MS

      Affiliations

    • Division of Biostatistics, Pediatrics Epidemiology Center, University of South Florida Health, Tampa, Fla.
    • ,
  • Murray L. Shames, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, University of South Florida Health, Tampa, Fla
    • ,
  • Brad L. Johnson, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, University of South Florida Health, Tampa, Fla
    • ,
  • Dennis F. Bandyk, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, University of South Florida Health, Tampa, Fla

Received 16 January 2007 ,Accepted 24 July 2007.

  • Image Result

    Kaplan-Meier estimates of primary, assisted, and secondary patency for 130 infrainguinal polytetrafluoroethylene bypasses according to duplex surveillance. The number of at-risk bypasses is shown at 6

    Kaplan-Meier estimates of primary, assisted, and secondary patency for 130 infrainguinal polytetrafluoroethylene bypasses according to duplex surveillance. The number of at-risk bypasses is shown at 6 months and annual follow-up intervals; standard error (SE) remained less than 10% until 4 years. Significant patency augmentation (log rank; P = .025) was accomplished through secondary interventions on stenotic and occluded bypasses.

  • Image Result
    Thrombotic outcome of low-flow (midgraft peak velocity ≤45 cm/s) infrainguinal bypasses (n = 61). A significant patency benefit was seen for therapeutic warfarin over subtherapeutic or no anticoagulat

    Thrombotic outcome of low-flow (midgraft peak velocity ≤45 cm/s) infrainguinal bypasses (n = 61). A significant patency benefit was seen for therapeutic warfarin over subtherapeutic or no anticoagulation (sub/no) for both above-knee popliteal (P = .03) and below-knee target grafts (P = .0004).

  • Image Result
    Thrombotic outcome of high-flow (midgraft peak velocity >45 cm/s) bypasses (n = 69). No additional benefit of therapeutic warfarin was found for infrainguinal bypasses (P = .15), including above-knee

    Thrombotic outcome of high-flow (midgraft peak velocity >45 cm/s) bypasses (n = 69). No additional benefit of therapeutic warfarin was found for infrainguinal bypasses (P = .15), including above-knee (P = .27) and below-knee (P = .38) target subgroups. Sub/no, Subtherapeutic or no anticoagulation.

 Competition of interest: none.

 CME article

PII: S0741-5214(07)01263-3

doi: 10.1016/j.jvs.2007.07.046

Journal of Vascular Surgery
Volume 46, Issue 6 , Pages 1160-1166 , December 2007

Article Tools

* Image Usage & Resolution